Kantaro Sees Important Role For New Antibody Test During Next Phase Of Pandemic

The company is planning to produce up to 10 million COVID-SeroKlir SARS-CoV-2 IgG antibody test kits a month through a partnership with Bio-Techne.

The coronavirus spike protein that mediates coronavirus entry into host cell
• Source: shutterstock.com (Design Cells/Getty Images/iStockphoto)

Kantaro Biosciences, LLC , a joint venture between Mount Sinai Health System and Renalytix AI plc , expects its SARS-CoV-2 IgG antibody test kit will allow researchers and public health officials to track the effectiveness of the COVID-19 vaccination programs that will likely begin soon.

“We're approaching a tipping point in the pandemic … where we're going to be moving into a very significant need...

More from Clinical Trials

More from R&D